Peer AI Built an Agentic Platform That Transforms Life Sciences Regulatory Documentation

Pharmaceutical and biotech companies spend years bringing a drug to market. Most people assume the bottleneck is the science. It rarely is. Preparing an IND, a CTA, a Clinical Study Report, or an Investigator Brochure requires weeks of coordinated effort across scientific, clinical, and regulatory teams. Each document draws from pharmacology studies, toxicology reports, CMC data, and clinical trial results. That data lives in disconnected systems, maintained by different teams, and rarely formatted with downstream documentation in mind.

That fragmentation had a direct cost. Teams could not generate a document from a single source of truth. They had to manually locate data, align it across multiple in-progress outputs, and reconcile inconsistencies before any draft could be considered complete. A change in one document triggered a cascade of revisions across others. Adding more people to the process did not fix it. It added more coordination overhead to a system that was already breaking under its own weight.

Compliance made the stakes higher. Regulatory submissions are reviewed by agencies where even minor inconsistencies can delay an approval or trigger a request for additional information. Speed was never the only variable. Every document had to be accurate, traceable to its source, and consistent with everything else in the package. Teams that tried to move faster often introduced the exact errors that slowed them down.

The real loss was time. Scientists and regulatory professionals were spending the majority of their working hours rewriting, validating, and aligning documents rather than advancing the science those documents were meant to describe. That was the problem Peer AI set out to fix.

The starting point was architecture. A generic AI writing tool would not survive contact with life sciences regulatory requirements. The platform needed to understand the structure of regulatory submissions, the relationships between documents, and the compliance standards each output had to meet. Cogent Labs built that foundation first, designing a multi-agent system where specialized AI agents handle distinct stages of the document lifecycle from initial drafting through data propagation, cross-document alignment, and quality control.

Each agent carries a specific function. One handles generation of complex regulatory documents including IND and CTA applications, Investigator Brochures, Clinical Study Reports, and safety narratives. Another manages data mapping, pulling from pre-clinical, clinical, and CMC data sources and propagating updates consistently across all documents in a submission package. A third reviews outputs against regulatory standards before they reach a human reviewer. These agents do not work in sequence. They collaborate across the lifecycle, catching inconsistencies before they compound.

The intelligent template builder gave the platform lasting organizational value. Rather than treating each engagement as a standalone task, the system builds reusable, organization-specific templates aligned with a company's regulatory writing style, internal standards, and the requirements of their target agencies. Over time, the platform becomes more precise to the organization using it.

The infrastructure was built to match the sensitivity of the data it handles. SOC 2 and GDPR compliance frameworks, zero data retention policies, model isolation, and encrypted segmented infrastructure were designed in from day one, meeting the security requirements of enterprise pharma organizations before they even asked.

The most immediate impact was speed. Regulatory documents that previously required weeks of coordinated manual effort can now be drafted, validated, and aligned in a fraction of that time. That compression changes the tempo of the entire regulatory process. Timelines that organizations had accepted as fixed constraints turned out to be a product of the process, not the science.

The elimination of manual rework was equally significant. Automated data propagation means a change at the source flows through every affected document automatically. Teams that once spent days reconciling inconsistencies now operate from a single, consistent data layer. That is not just an efficiency gain. It removes the compliance risk that comes with human error in high-stakes documentation.

The platform is trusted by organizations across the full spectrum, from emerging biotechs building their first regulatory submissions to top 20 pharma companies managing complex, multi-program pipelines. That range of adoption reflects both the platform's scalability and the universality of the problem it solves. Regulatory documentation is a burden at every size. Peer AI removes it at every size.

• Agentic AI-powered documentation with multi-agent orchestration across the full document lifecycle, from pre-clinical through CMC and Module 3

• Human-level output quality meeting benchmarks in accuracy, readability, consistency, and completeness

• Enterprise-grade security with SOC 2 and GDPR compliance, zero data retention, and encrypted segmented infrastructure

• Trusted across the spectrum from emerging biotechs to top 20 pharma companies managing complex, multi-program pipelines

Peer AI had the scientific vision and the regulatory expertise. What they were missing was a system sophisticated enough to handle the structural, repetitive, and data-intensive work without introducing new compliance risks in the process. That gap is not unique to their clients. It exists in every organization where highly trained professionals spend their days managing documentation rather than advancing the work that actually requires their expertise.

What Cogent Labs built with Peer AI illustrates a pattern that repeats across regulated industries. The value of agentic AI is not in replacing expert judgment. It is in removing everything around it that does not require it. When the drafting is automated, the data propagation is automated, and the consistency checks are automated, what remains is the work only a scientist or regulatory professional can do. That is where their time should go.

The same principle applies to any domain where compliance, precision, and specialist knowledge sit at the center of the workflow. When the gap between scientific progress and regulatory submission depends entirely on manual effort, speed becomes a structural disadvantage. Closing that gap is not an operational improvement. It is what gets drugs to patients faster.